NeoStem Wins NIH Grant

October 7, 2009 (FinancialWire) — NeoStem, Inc. (AMEX: NBS) (Current Market Cap: $16.65 Mil.) said it has been awarded a grant of $108,746 for the repair of bone defects by human stem cells from the National Institutes of Health.

This award will fund studies to investigate the potential of very small embryonic-like stem cells to regenerate bone in an animal model. The stem cells are isolated from adults’ own peripheral blood using NeoStem’s proprietary isolation methods.

NeoStem said the grant was awarded under a new NIH program designed to support large-scale research projects that accelerate critical breakthroughs, early and applied research on technologies, and new approaches to improve the synergy and interactions among multi and interdisciplinary research teams.

The program is intended for research activities that have high, short-term impact, and a high likelihood of enabling growth and investment in biomedical research and development in new fields of investigation.

New York-based NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own stem cells when they are young and healthy for their personal use in times of future medical need.

The company has also entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate very small embryonic-like stem cells.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).